349 related articles for article (PubMed ID: 17407040)
1. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.
Tenover FC; Moellering RC
Clin Infect Dis; 2007 May; 44(9):1208-15. PubMed ID: 17407040
[TBL] [Abstract][Full Text] [Related]
2. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
Hussain FM; Boyle-Vavra S; Shete PB; Daum RS
J Infect Dis; 2002 Sep; 186(5):661-7. PubMed ID: 12195353
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Appleman MD; Citron DM
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
[TBL] [Abstract][Full Text] [Related]
4. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.
Franchi D; Climo MW; Wong AH; Edmond MB; Wenzel RP
Clin Infect Dis; 1999 Dec; 29(6):1566-8. PubMed ID: 10585815
[TBL] [Abstract][Full Text] [Related]
5. [Susceptibility of Staphylococcus aureus biofilms to vancomycin, gemtamicin and rifampin].
Kotulová D; Slobodníková L
Epidemiol Mikrobiol Imunol; 2010 Apr; 59(2):80-7. PubMed ID: 20586169
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
7. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
8. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period.
Wang G; Hindler JF; Ward KW; Bruckner DA
J Clin Microbiol; 2006 Nov; 44(11):3883-6. PubMed ID: 16957043
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
[TBL] [Abstract][Full Text] [Related]
10. Glycopeptide and oxacillin activity against Staphylococcus aureus isolates at a tertiary care center in Lebanon.
Kanj SS; Ghaleb PA; Araj GF
J Med Liban; 2004; 52(1):8-12. PubMed ID: 15881695
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of fluoroquinolones, vancomycin, and gentamicin against methicillin-resistant Staphylococcus aureus ocular isolates.
Kotlus BS; Wymbs RA; Vellozzi EM; Udell IJ
Am J Ophthalmol; 2006 Nov; 142(5):726-9. PubMed ID: 17056356
[TBL] [Abstract][Full Text] [Related]
13. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
Jones RN
Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
15. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
17. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibition of coagulase-negative staphylococci by vancomycin/aminoglycoside-loaded cement spacers.
Streuli JC; Exner GU; Reize CL; Merkofer C; Scott CP; Zbinden R
Infection; 2006 Apr; 34(2):81-6. PubMed ID: 16703297
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains.
Bhateja P; Purnapatre K; Dube S; Fatma T; Rattan A
Int J Antimicrob Agents; 2006 Mar; 27(3):201-11. PubMed ID: 16417988
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.
Whitener CJ; Park SY; Browne FA; Parent LJ; Julian K; Bozdogan B; Appelbaum PC; Chaitram J; Weigel LM; Jernigan J; McDougal LK; Tenover FC; Fridkin SK
Clin Infect Dis; 2004 Apr; 38(8):1049-55. PubMed ID: 15095205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
